Innovating Works

ABLAVIEW

Financiado
An Innovative Image Guided Radiofrequency Ablation System to treat Atrial Fibril...
Medlumics innovation, AblaView™ is an optically guided radiofrequency (RF) ablation catheter to treat atrial fibrillation and arrhythmias. The AblaView™ technology is based on Optical Coherence Reflectometry) which in turn allows... Medlumics innovation, AblaView™ is an optically guided radiofrequency (RF) ablation catheter to treat atrial fibrillation and arrhythmias. The AblaView™ technology is based on Optical Coherence Reflectometry) which in turn allows the Electrophysiologist to view the ablation of precise areas of the myocardial tissue inside the heart in real time for the treatment of Atrial fibrillation. Atrial Fibrilation is the most common type of heart arrhythmia. An estimated 33.5 million people worldwide suffered from AF and prevalence of the disease is expected to increase as the number of people over the age of 65 continues to expand. There were 491.000 catheter-based procedures carried out worldwide in 2015. AblaView is a first-in-class optically guided radio-frequency ablation system to provide missing information about the local catheter environment and directly assess lesion progress in real time by probing the tissue surrounding the ablation electrode. The key disruptive nature of MedLumics’ AblaView™ technology is both been able to precisely control and visualize in real-time tissue ablation at the desired sites of AF propagation but without over-treatment or indeed ablation of healthy tissue. The current technologies do not allow for this level of control or visualization and consequently expose the AF patient to inappropriate ablations and serious side effects or adverse events. MedLumics’ technology addresses exactly that problem with its AblaView catheter: it will provide the clinicians with direct, real-time information on lesion formation in the tissue surrounding the catheter’s radiofrequency electrode during the ablation process. Although AF patients are expected to benefit most from this innovation, AblaView is also expected to improve the accuracy of other arrhythmia ablation procedures. ver más
30/04/2023
4M€
Duración del proyecto: 48 meses Fecha Inicio: 2019-04-12
Fecha Fin: 2023-04-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2023-04-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
Presupuesto El presupuesto total del proyecto asciende a 4M€
Líder del proyecto
MEDLUMICS El desarrollo, producción y comercialización de equipos y programas informáticos para aplicaciones médicas. se excluyen de este objeto todas...
Perfil tecnológico TRL 4-5 1M